CD274 and hematologic disorder: These have been best described in cHL in which 9p24.1 amplification in cHL is associated with higher expression of PD-L1 and worse progression-free survival (PFS).24 Similar to solid malignancies, higher PD-L1 expression in cHL has been associated with improved prognosis when treated with nivolumab.18 Therefore, it is important to understand the characteristics of TMB and PD-1/PD-L1 in hematologic malignancies, which we explore in this report.